Skip to main content
Download PDF
- Main
CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP
- Rojas, Julio C;
- Bang, Jee;
- Lobach, Iryna V;
- Tsai, Richard M;
- Rabinovici, Gil D;
- Miller, Bruce L;
- Boxer, Adam L;
- Williams, David;
- Lafontaine, Anne Louise;
- Marras, Connie;
- Jog, Mandar;
- Panisset, Michael;
- Lang, Anthony;
- Parker, Lesley;
- Stewart, Alistair J;
- Corvol, Jean-Christophe;
- Azulay, Jean-Philippe;
- Couratier, Philippe;
- Mollenhauer, Brit;
- Lorenzl, Stefan;
- Ludolph, Albert;
- Benecke, Reiner;
- Hoglinger, Gunter;
- Lipp, Axel;
- Reichmann, Heinz;
- Woitalla, Dirk;
- Chan, Dennis;
- Zermansky, Adam;
- Burn, David;
- Lees, Andrew;
- Gozes, Illana;
- Boxer, Adam;
- Miller, Bruce L;
- Lobach, Iryna V;
- Roberson, Erik;
- Honig, Lawrence;
- Zamrini, Edward;
- Pahwa, Rajesh;
- Bordelon, Yvette;
- Driver-Dunkley, Erika;
- Lessig, Stephanie;
- Lew, Mark;
- Womack, Kyle;
- Boeve, Brad;
- Ferrara, Joseph;
- Hillis, Argyle;
- Kaufer, Daniel;
- Kumar, Rajeev;
- Xie, Tao;
- Gunzler, Steven;
- Zesiewicz, Theresa;
- Dayalu, Praveen;
- Golbe, Lawrence;
- Grossman, Murray;
- Jankovic, Joseph;
- McGinnis, Scott;
- Santiago, Anthony;
- Tuite, Paul;
- Isaacson, Stuart;
- Leegwater-Kim, Julie;
- Litvan, Irene;
- Knopman, David S;
- Schneider, Lon S;
- Doody, Rachelle S;
- Koestler, Mary;
- Jack, Clifford R;
- Van Deerlin, Viviana;
- Randolph, Christopher;
- Whitaker, Steve;
- Hirman, Joe;
- Gold, Michael;
- Morimoto, Bruce H
Published Web Location
https://doi.org/10.1212/wnl.0000000000004859Abstract
Objective
To determine the ability of CSF biomarkers to predict disease progression in progressive supranuclear palsy (PSP).Methods
We compared the ability of baseline CSF β-amyloid1-42, tau, phosphorylated tau 181 (p-tau), and neurofilament light chain (NfL) concentrations, measured by INNO-BIA AlzBio3 or ELISA, to predict 52-week changes in clinical (PSP Rating Scale [PSPRS] and Schwab and England Activities of Daily Living [SEADL]), neuropsychological, and regional brain volumes on MRI using linear mixed effects models controlled for age, sex, and baseline disease severity, and Fisher F density curves to compare effect sizes in 50 patients with PSP. Similar analyses were done using plasma NfL measured by single molecule arrays in 141 patients.Results
Higher CSF NfL concentration predicted more rapid decline (biomarker × time interaction) over 52 weeks in PSPRS (p = 0.004, false discovery rate-corrected) and SEADL (p = 0.008), whereas lower baseline CSF p-tau predicted faster decline on PSPRS (p = 0.004). Higher CSF tau concentrations predicted faster decline by SEADL (p = 0.004). The CSF NfL/p-tau ratio was superior for predicting change in PSPRS, compared to p-tau (p = 0.003) or NfL (p = 0.001) alone. Higher NfL concentrations in CSF or blood were associated with greater superior cerebellar peduncle atrophy (fixed effect, p ≤ 0.029 and 0.008, respectively).Conclusions
Both CSF p-tau and NfL correlate with disease severity and rate of disease progression in PSP. The inverse correlation of p-tau with disease severity suggests a potentially different mechanism of tau pathology in PSP as compared to Alzheimer disease.Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
For improved accessibility of PDF content, download the file to your device.
Enter the password to open this PDF file:
File name:
-
File size:
-
Title:
-
Author:
-
Subject:
-
Keywords:
-
Creation Date:
-
Modification Date:
-
Creator:
-
PDF Producer:
-
PDF Version:
-
Page Count:
-
Page Size:
-
Fast Web View:
-
Preparing document for printing…
0%